Related Experiment Videos
Improving the outcome of septic shock in children
Erica A. Kirsch1, Brett P. Giroir
1aDepartment of Pediatrics,Wilford Hall Medical Center, Lackland AFB, Texas, USA and bDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Insights
Improving pediatric sepsis outcomes requires multifaceted strategies. Research explores immune mediators and genetic factors for novel anti-sepsis therapies, aiming to reduce child morbidity and mortality.
Area of Science:
- Pediatric critical care medicine
- Infectious disease immunology
Background:
- Sepsis significantly contributes to child morbidity and mortality.
- Effective sepsis management necessitates comprehensive approaches: prevention, early detection, prompt treatment, and tailored care.
Purpose of the Study:
- To review current advancements in pediatric sepsis management.
- To highlight potential therapeutic targets, including immune mediators and coagulation factors.
- To discuss the role of host response in sepsis pathophysiology.
Main Methods:
- Review of existing literature on pediatric sepsis therapies.
- Analysis of studies investigating immunomodulatory agents.
- Exploration of genetic factors influencing sepsis outcomes.
Main Results:
- Granulocyte colony-stimulating factor shows potential for neonatal sepsis prevention.
- Clindamycin may inhibit endotoxin release.
- Bactericidal/permeability-increasing protein (rBPI21) improved outcomes in meningococcal disease.
- Pentoxifylline improved sepsis outcomes in premature infants.
Conclusions:
- Further randomized controlled trials of immunomodulatory agents are warranted.
- Genomic studies may personalize sepsis therapeutics by explaining outcome variability.
- Targeting immune and coagulation pathways offers promising avenues for anti-sepsis strategies.
Abstract:
Sepsis is an important cause of pediatric morbidity and mortality. Improving the outcome of pediatric sepsis requires diverse efforts, including prevention, early recognition, improvements in early management and transport, and physiology-directed care. Awareness that septic shock represents a pathophysiologic host response to infection has prompted investigation of immune mediators and coagulation factors as potential targets for anti-sepsis therapies. Advancements thus far include: the potential prevention of neonatal sepsis with granulocyte colony-stimulating factor; recognition of clindamycin as a potential inhibitor of endotoxin release; improved outcome from meningococcal disease in children treated with bactericidal/permeability-increasing protein (rBPI21); and improved outcome from sepsis in premature infants treated with pentoxifylline. Further randomized controlled studies of immunomodulatory agents are indicated and a few are in progress. Current studies on genetic propensities in cytokine and coagulation protein expression may explain variability in patient outcomes and eventually lead to genomics-based therapeutics.